Gene variant of the bradykinin B2 receptor influences pulmonary arterial pressures in heart failure patients

Clinical Medicine: Circulatory, Respiratory and Pulmonary Medicine

Volumn 2009, Issue 3, 2009, Pages 9-17

  Olson, Thomas P ^a   Frantz, Robert P ^a   Turner, Stephen T ^a   Bailey, Kent R ^a   Wood, Christina M ^a   Johnson, Bruce D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Genetics; Heart failure; Hemodynamics; Pulmonary hypertension

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ B2 RECEPTOR; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; ELECTROCARDIOGRAM; ENZYME BLOOD LEVEL; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

EID: 62849090490     PISSN: None     EISSN: 11781157     Source Type: Journal    
DOI: 10.4137/ccrpm.s2147     Document Type: Article

References (44)

1. Enriquez-Sarano M, FACC, Maurice Rossi M, Andrea Seward M, FACC, James B. Bailey P, and Kent R. Determinants of Pulmonary Hypertension in Left Ventricular Dysfunction. Journal of the American College of Cardiology. 1997;29:153-159.
2. Tribouilloy C, Enriquez-Sarano M, Rossi A, Tajik A, Seward J. Determinants of the pulmonary artery pressure rise in left ventricular dysfunction. Cardiologia. 1997;42:1051-1058.
3. Cheever K. An overview of pulmonary arterial hypertension: risks, pathogenesis, clinical manifestations, and management. J Cardiovasc Nurs. 2005;20:108-116.
4. Lefebvre F, Prefontaine A, Calderone A, Caron A, et al. Modification of the pulmonary renin-angiotensin system and lung structural remodeling in congestive heart failure. Clin Sci. 2006;111:217-224.
5. Stewart JM, Gera L, Chan DC, Whalley ET, Hanson WL, Zuzack JS. Potent, long-acting bradykinin antagonists for a wide range of applications. Can J Physiol Pharmacol. 1997;75:719-724.
6. Drummond GF, Cocks TM. Endothelium-dependent relaxation to the B1 kinin receptor agonist des-Arg9-bradykinin in human coronary arteries. Br J Pharmacol. 1995;116:3083-3095.
7. McLean PG, Perretti M, Ahluwalia A. Kinin B1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res. 2000;48:194-210.
8. Marin-Castano ME, Schanstra JP, Neau E, Praddaude F, et al. Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 2002;105:627-632.
9. Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, Ritter JM. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol. 1994;38:317-321.
10. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102:2190-2196.
11. Taraseviciene-Stewart L, Scerbavicius R. Stewart JM, et al. Treatment of severe pulmonary hypertension: A bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides. 2005;26:1292-1300.
12. Kammerer S, Braun A, Arnold N, Roscher AA. The human bradykinin B2 receptor gene: full length cDNA, genomic organization and identification of the regulatory region. Biochem Biophys Res Commun. 1995;211:226-233.
13. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin converting exzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
14. Benacerraf S, Carville C, Adnot S, et al. Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by Quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. J Cardiovasc Pharmacol. 1999;34:368-373.
15. Squire IB, O'Kane KP, Anderson N, Reid JL. Bradykinin B2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension. 2000;36:132-136.
16. Schiller NH, Shah PM, Crawford M, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:158-367.
17. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984;74:657-662.
18. Berger M, Haimowitz A, van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6:359-365.
19. Currie PJ, Sweard JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, et al. Continuous wave Doppler determination of right ventricular pressure: A simultaneous Doppler-catheterzation study in 127 patients. J Am Coll Cardial. 1985;6:750-756.
20. Lanzarini L, Fontana A, Lucca E, Campana C, Klersy C. Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure. Am Heart J. 2002b;144:1087-1094.
21. Troy BL, Pombo J, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation. 1972;45:602-611.
22. Lewis JF, Kuo LC, Nelson JG, Limacher MC, Quinones MA: Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation. 1984;70:425-431.
23. Parisi AF, Moynihan PF, Feldman CL, Folland ED. Approaches to determination of left ventricular volume and ejection fraction by real-time two-dimensional echocardiography. Clin Cardiol. 1979;2:257-263.
24. Braun A, Kammerer S, Bohme E, Muller B, Roscher AA. Identification of polymorphic sites of the human bradykinin B2 receptor gene. Biochem Biophys Res Commun. 1995;211:234-240.
25. Group CS. Effects of enalapril on mortalit in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1436.
26. Cohn JN, Johnson G, Zeische S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
27. Investigators AS. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
28. Abraham MR, Olson LJ, Joyner MJ, Turner ST, Beck KC, Johnson BD. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation. 2002;106:1794-1799.
29. Flapan AD, Shaw TR, Edwards CR, Davies E, Williams BC. Contrasting patterns of arterial and venous dilation after intravenous captopril in patients with chronic cardiac failure and their relationship to plasma angiotensin II concentrations. Am Heart J. 1992;124:1270-1276.
30. Kuga T, Mohri M, Egashira K, et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol. 1997;30:108-112.
31. Cherry PD, Furchgott R, Zawadzki J, Jothianandan D. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA. 1982;79:2106-2110.
32. Bonner G, Preis S, Schunk U, Wagmann M, Chrosch R, Toussaint C. Effect of bradykinin on arteries and veins in systemic and pulmonary circulation. J Cardiovasc Pharmacol. 1992;20:S21-S27.
33. O'Kane KP, Webb DJ, Collier JG, Vallance PJ. Local L-NG-monomethyl-agrinine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol. 1994;38:311-315.
34. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
35. Honing ML, Smits P, Morrison PJ, Rakelinik TJ. Bradykinin-induced vasodilation of human forearm resistance cessels is primarily mediated by endothlium-dependent hyperpolarization. Hypertension. 2000;35:1314-1318.
36. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989;412:543-555.
37. Bonner G, Preis S, Schunk U, Toussaint C, Kauffmann W. Hemodynamic effects of bradykinin and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15:S45-S56.
38. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
39. Dhamrait SS, Payne JR, Li P, et al. Humphries SE and Montgomery HE. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J. 2003;24:1672-1680.
40. Pretorius MM, Gainer JV, Van Guilder GP, et al. The bradykinin type 2 receptor BE1 polymorphism and ethnicity infl uences systolic blood pressure and vascular resistance. Clin Pharmacol Ther. 2007.
41. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001;103:1644-1648.
42. Roden DM, Brown NJ. Prescribing Genotyping: Not yet ready for prime time, but getting there. Circulation. 2001;103:1608-1610.
43. McNamara DM, MacGowan GA, London B. Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease. Am J Pharmacogenomics. 2002;2:73-78.
44. Lanzarini L, Fontana A, Lucca E, Campana C, Klersy C. Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure. Am Heart J. 2002a;144:1087-1094.